D-0816-2021 Class II

Recalled by Morton Grove Pharmaceuticals, Inc. — Morton Grove, IL

FDA drug recall D-0816-2021 was initiated by Morton Grove Pharmaceuticals, Inc. on Sep 3, 2021 and is designated Class II. Reason for recall: CGMP Deviations: Potential concern with products manufactured using liquid sugar batches contaminated with microbial organisms. Affected quantity: 38,748 bottles.

Recall details

Product Type
Drugs
Report Date
Sep 29, 2021
Initiation Date
Sep 3, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
38,748 bottles

Product description

Valproic Acid Oral Solution USP, (250 mg/5 mL), 1 Pint (473 mL), Rx Only, Manufactured For: Wockhardt USA, LLC, Parsippany, NJ 07054; Manuractured By: Morton Grove Pharmaceuticals, Inc, Morton Grove, IL 60053. NDC: 60432-621-16

Reason for recall

CGMP Deviations: Potential concern with products manufactured using liquid sugar batches contaminated with microbial organisms.

Distribution pattern

Nationwide USA and China

Code information

Lot #: UV1159

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0816-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0816-2021. Report a data issue: hello@regdatalab.com.